Vol. 3 No. 9 (2023)
Reimbursement Reviews

Difelikefalin (Korsuva)

Published September 27, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses difelikefalin (Korsuva), 50 mcg/mL, IV.
  • Indication: For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on hemodialysis.